This category page covers biotechnology and pharmaceutical companies developing JAK-STAT pathway inhibitors specifically for Alzheimer's disease. The JAK-STAT (Janus Kinase/Signal Transducer and Activator of Transcription) pathway is a critical signaling cascade in neuroinflammation, mediating cytokine-driven microglial activation, astrocyte reactivity, and neuronal dysfunction in Alzheimer's disease.
Key targets include:
The JAK-STAT pathway in Alzheimer's disease[1][2]:
Inhibiting this pathway at various nodes can reduce neuroinflammation while potentially preserving beneficial cytokine signaling[3].
| Company | Drug | Target | Mechanism | Phase | Trial |
|---|---|---|---|---|---|
| Eli Lilly | Baricitinib | JAK1/JAK2 | Direct inhibition | Phase 2 | NCT05283460 |
| INmune Bio | XPro1595 | Soluble TNF-α | Ligand neutralization (upstream of JAK-STAT) | Phase 2 | NCT05318976 |
| Galapagos | Filgotinib | JAK1 | Selective inhibition | Preclinical | — |
| Biohaven | STAT3 inhibitors | STAT3 | Transcription factor | Discovery | — |
Drug: Baricitinib (Olumiant)
Indication: Alzheimer's disease
Stage: Phase 2 (NCT05283460)
Background:
Baricitinib is an FDA-approved JAK1/JAK2 inhibitor for rheumatoid arthritis and COVID-19. Eli Lilly is evaluating baricitinib in AD based on evidence that JAK-STAT inhibition reduces neuroinflammation and may preserve cognitive function.
Mechanism:
Related Pages:
Drug: XPro1595
Indication: Alzheimer's disease
Stage: Phase 2 (NCT05318976)
Background:
INmune Bio is developing XPro1595, a dominant-negative TNF inhibitor that acts upstream of the JAK-STAT pathway. By selectively neutralizing soluble TNF-alpha (while preserving membrane-bound TNF), XPro1595 reduces the cytokine signal that activates JAK-STAT signaling.
Mechanism:
Related Pages:
Drug: Filgotinib (Jyseleca)
Indication: Alzheimer's disease (research)
Stage: Preclinical
Background:
Galapagos developed filgotinib, a selective JAK1 inhibitor approved for rheumatoid arthritis in EU and Japan. While not currently in AD clinical trials, filgotinib represents a candidate for JAK1-selective inhibition in neurodegeneration.
Mechanism:
Related Pages:
Focus: STAT3 targeting and cytokine modulation
Lead Candidates: Troriluzole, STAT3 inhibitors
Indication: Alzheimer's disease
Stage: Preclinical/research
Mechanism: Targeting downstream STAT3 transcription factor to block neuroinflammatory gene expression
Notes: Broad neuroscience pipeline including TDP-43 and glutamate modulation programs
| Approach | Target | Example | Advantages | Disadvantages |
|---|---|---|---|---|
| Direct JAK Inhibition | JAK1/JAK2 | Baricitinib | Broad suppression of cytokine signaling | Immunosuppression risk |
| JAK1-Selective | JAK1 | Filgotinib | More selective, potentially better safety | Less broad effect |
| Ligand Neutralization | TNF-α | XPro1595 | Preserves some cytokine signaling | Only targets one cytokine |
| STAT3 Inhibition | STAT3 | In development | Direct downstream blockade | Limited BBB-penetrant options |
| Company | Drug | NCT Number | Phase | Status |
|---|---|---|---|---|
| INmune Bio | XPro1595 | NCT05318937 | Phase 2 | Recruiting |
| Academic | Baricitinib | NCT05283460 | Phase 2 | Active |
| Academic | Baricitinib | NCT05559177 | Phase 2 | Active |
JAK/STAT signaling in Alzheimer's disease: implications for therapy. Journal of Neuroinflammation. 2020. ↩︎
Microglial JAK-STAT3 activation drives progressive dopaminergic neurodegeneration. Nature Neuroscience. 2024. ↩︎
STAT3 as a therapeutic target in Alzheimer's disease. Nature Reviews Neurology. 2023. ↩︎
Baricitinib crosses the blood-brain barrier: implications for JAK inhibitor use in neurodegeneration. Clinical Pharmacokinetics. 2022. ↩︎